JP7832128B2 - 心房機能不全の治療 - Google Patents

心房機能不全の治療

Info

Publication number
JP7832128B2
JP7832128B2 JP2022577105A JP2022577105A JP7832128B2 JP 7832128 B2 JP7832128 B2 JP 7832128B2 JP 2022577105 A JP2022577105 A JP 2022577105A JP 2022577105 A JP2022577105 A JP 2022577105A JP 7832128 B2 JP7832128 B2 JP 7832128B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
patient
composition according
atrial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022577105A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529502A5 (enExample
JP2023529502A (ja
Inventor
タンビー，ジャン－フランソワ
エム エデルバーグ，ジェイ
ハワード タケオ クリオ，グレゴリー
ライル ケリー，シンシア
ヤン，チュン
パトリック ヘンツェ，マーカス
リオ，カルロス エル デル
リー アンダーソン，ロバート
ピー スマンデア，モーリス
ガンジュ，ジテンドラ
Original Assignee
マイオカーディア，インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マイオカーディア，インク filed Critical マイオカーディア，インク
Publication of JP2023529502A publication Critical patent/JP2023529502A/ja
Publication of JP2023529502A5 publication Critical patent/JP2023529502A5/ja
Priority to JP2025252108A priority Critical patent/JP2026048841A/ja
Application granted granted Critical
Publication of JP7832128B2 publication Critical patent/JP7832128B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
JP2022577105A 2020-06-15 2021-06-14 心房機能不全の治療 Active JP7832128B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025252108A JP2026048841A (ja) 2020-06-15 2025-12-16 心房機能不全の治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063039438P 2020-06-15 2020-06-15
US63/039,438 2020-06-15
US202063042512P 2020-06-22 2020-06-22
US63/042,512 2020-06-22
PCT/US2021/037230 WO2021257456A1 (en) 2020-06-15 2021-06-14 Treatment of atrial dysfunction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025252108A Division JP2026048841A (ja) 2020-06-15 2025-12-16 心房機能不全の治療

Publications (3)

Publication Number Publication Date
JP2023529502A JP2023529502A (ja) 2023-07-10
JP2023529502A5 JP2023529502A5 (enExample) 2024-06-24
JP7832128B2 true JP7832128B2 (ja) 2026-03-17

Family

ID=76845320

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022577105A Active JP7832128B2 (ja) 2020-06-15 2021-06-14 心房機能不全の治療
JP2025252108A Pending JP2026048841A (ja) 2020-06-15 2025-12-16 心房機能不全の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025252108A Pending JP2026048841A (ja) 2020-06-15 2025-12-16 心房機能不全の治療

Country Status (13)

Country Link
US (1) US20230233545A1 (enExample)
EP (1) EP4164644A1 (enExample)
JP (2) JP7832128B2 (enExample)
KR (1) KR20230024977A (enExample)
CN (1) CN116056703A (enExample)
AU (1) AU2021293817A1 (enExample)
BR (1) BR112022025551A2 (enExample)
CA (1) CA3180943A1 (enExample)
CL (1) CL2022003548A1 (enExample)
IL (1) IL298885A (enExample)
MX (1) MX2022015488A (enExample)
TW (1) TW202214241A (enExample)
WO (1) WO2021257456A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11759640B2 (en) * 2022-01-07 2023-09-19 Xyra, Llc Methods for reducing the risk of strokes by pharmacotherapy to reduce the number and duration of atrial fibrillations
CN116082326B (zh) * 2022-12-16 2024-12-27 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途
CN119157623A (zh) * 2023-12-12 2024-12-20 成都迈格因科技有限公司 一种经导管心脏射频消融的蒸汽爆破安全预警和控制系统
CN117815534A (zh) * 2023-12-12 2024-04-05 苏州晟智医疗科技有限公司 反搏辅助装置、计算设备、存储介质及反搏系统
CN118304374A (zh) * 2024-04-01 2024-07-09 山东省中医药研究院附属医院 一种组合物在制备治疗心动过速和/或瓣膜反流药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502883A (ja) 2015-01-22 2018-02-01 マイオカーディア，インク 拡張型心筋症（ｄｃｍ）の処置のための４−メチルスルホニル置換ピペリジンウレア化合物
WO2019006235A1 (en) 2017-06-30 2019-01-03 Amgen Inc. METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10758525B2 (en) * 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
JP2020519628A (ja) * 2017-05-10 2020-07-02 インカーダ セラピューティクス， インコーポレイテッド 肺投与によって心臓の状態を処置するための単位用量、エアロゾル、キットおよび方法
CA3138080A1 (en) * 2019-05-19 2020-11-26 Jean-Francois TAMBY Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl) n-(isoxazol-3-yl)piperidine-1-carboxamid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502883A (ja) 2015-01-22 2018-02-01 マイオカーディア，インク 拡張型心筋症（ｄｃｍ）の処置のための４−メチルスルホニル置換ピペリジンウレア化合物
WO2019006235A1 (en) 2017-06-30 2019-01-03 Amgen Inc. METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
John R Teerlink et al.，"Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study"，Lancet，2011年，Vol.378，p.667-675
Sarah Fernandes et al.，"MYK-491, a Novel Small-Molecule Cardiac Myosin Activator Increases Cardiac Systolic Function and Preserves Mechanical Efficiency: Pre-Clinical in vivo and in vitro Evidence"，Circulation，2019年，Vol.140, No.Suppl_1，Abstract 15707

Also Published As

Publication number Publication date
BR112022025551A2 (pt) 2023-03-07
CA3180943A1 (en) 2021-12-23
EP4164644A1 (en) 2023-04-19
MX2022015488A (es) 2023-03-21
AU2021293817A1 (en) 2023-01-19
CN116056703A (zh) 2023-05-02
CL2022003548A1 (es) 2023-06-09
US20230233545A1 (en) 2023-07-27
IL298885A (en) 2023-02-01
KR20230024977A (ko) 2023-02-21
WO2021257456A1 (en) 2021-12-23
JP2026048841A (ja) 2026-03-17
TW202214241A (zh) 2022-04-16
JP2023529502A (ja) 2023-07-10

Similar Documents

Publication Publication Date Title
JP2026048841A (ja) 心房機能不全の治療
US12616697B2 (en) Methods of treatment with myosin modulator
US20250241903A1 (en) Treatment of systolic dysfunction
JP7830321B2 (ja) ミオシンモジュレーターによる治療方法
AU2023210548A1 (en) Methods of treating heart failure with reduced ejection fraction with dapagliflozin
US20250325531A1 (en) Treatment of systolic dysfunction
HK40091633A (zh) 心房功能障碍的治疗
HK40077232A (en) Methods of treatment with myosin modulator
EA052373B1 (ru) Способы лечения модулятором миозина
CN101065135A (zh) 涉及心力衰竭的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240613

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260305

R150 Certificate of patent or registration of utility model

Ref document number: 7832128

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150